NYSE:ATNM Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis $1.50 -0.05 (-3.23%) Closing price 04:00 PM EasternExtended Trading$1.53 +0.03 (+2.00%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Actinium Pharmaceuticals Stock (NYSE:ATNM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ATNM alerts:Sign Up Key Stats Today's Range$1.47▼$1.6250-Day Range$1.06▼$1.8952-Week Range$1.03▼$10.24Volume247,133 shsAverage Volume504,749 shsMarket Capitalization$46.79 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingModerate Buy Company OverviewActinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Read More… Actinium Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreATNM MarketRank™: Actinium Pharmaceuticals scored higher than 24% of companies evaluated by MarketBeat, and ranked 744th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingActinium Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageActinium Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Actinium Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Actinium Pharmaceuticals is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Actinium Pharmaceuticals is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioActinium Pharmaceuticals has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ATNM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ATNM. News and Social Media1.1 / 5News Sentiment-0.03 News SentimentActinium Pharmaceuticals has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Actinium Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 8 people have searched for ATNM on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.00% of the stock of Actinium Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 27.50% of the stock of Actinium Pharmaceuticals is held by institutions.Read more about Actinium Pharmaceuticals' insider trading history. Receive ATNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ATNM Stock News HeadlinesKirby McInerney LLP Urges Investors in Actinium Pharmaceuticals, Inc. (ATNM) to Inquire About Their Rights in Class Action LawsuitMay 5 at 8:00 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMMay 5 at 11:12 AM | globenewswire.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 5, 2025 | Golden Portfolio (Ad)The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc.(ATNM) ShareholdersMay 5 at 5:45 AM | prnewswire.comATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud LawsuitMay 4 at 12:13 PM | gurufocus.comATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud LawsuitMay 4 at 9:14 AM | prnewswire.comATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMay 2 at 4:00 PM | globenewswire.comClass Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors – Contact Levi & KorsinskyMay 2 at 1:48 PM | globenewswire.comSee More Headlines ATNM Stock Analysis - Frequently Asked Questions How have ATNM shares performed this year? Actinium Pharmaceuticals' stock was trading at $1.26 on January 1st, 2025. Since then, ATNM shares have increased by 19.0% and is now trading at $1.50. View the best growth stocks for 2025 here. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals, Inc. (NYSE:ATNM) announced its quarterly earnings data on Monday, August, 5th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.02. When did Actinium Pharmaceuticals' stock split? Shares of Actinium Pharmaceuticals reverse split on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Actinium Pharmaceuticals' major shareholders? Actinium Pharmaceuticals' top institutional shareholders include Creative Financial Designs Inc. ADV (0.34%). View institutional ownership trends. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Actinium Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Global Ship Lease (GSL), OPKO Health (OPK), Fitbit (FIT) and OHR Pharmaceutical (OHRP). Company Calendar Last Earnings8/05/2024Today5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ATNM Previous SymbolNYSE:ATNM CIK1388320 WebN/A Phone(646) 677-3870FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$2.00 Potential Upside/Downside+166.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,820,000.00 Net MarginsN/A Pretax Margin-50,512.35% Return on Equity-100.85% Return on Assets-47.89% Debt Debt-to-Equity RatioN/A Current Ratio10.25 Quick Ratio10.25 Sales & Book Value Annual Sales$81,000.00 Price / Sales577.70 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book1.15Miscellaneous Outstanding Shares31,196,000Free Float29,324,000Market Cap$46.79 million OptionableOptionable Beta-0.24 20 Stocks to Sell NowGet This Free Report This page (NYSE:ATNM) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.